Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.39 |
| ▸ | JAK2 | O60674 | 11/20 | 0.39 |
| ▸ | JAK1 | P23458 | 11/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372443 | 0.88 | JAK3 (0.38) | JAK3JAK2JAK1SYK | |
| SCHEMBL1368603 | 0.85 | JAK3 (0.57) | JAK3JAK2JAK1SYK | |
| SCHEMBL15755367 | 0.83 | JAK3 (0.43) | JAK3JAK2JAK1SYKKCNH2 | |
| SCHEMBL14795131 | 0.82 | GRM5 (0.43) | JAK3JAK2JAK1SYKKCNH2 | |
| SCHEMBL14795087 | 0.81 | JAK3 (0.41) | JAK3JAK2JAK1SYK | |
| SCHEMBL14795159 | 0.80 | NPC1 (0.47) | JAK3SYKKCNH2 | |
| SCHEMBL15755718 | 0.80 | JAK3 (0.41) | JAK3JAK2JAK1 | |
| SCHEMBL14795228 | 0.80 | JAK3 (0.41) | JAK3JAK2JAK1 | |
| SCHEMBL14795142 | 0.79 | JAK3 (0.40) | JAK3JAK2JAK1 | |
| SCHEMBL14795327 | 0.79 | JAK3 (0.35) | JAK3JAK2JAK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | claimed |
| CN-103003281-A | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | claimed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| CN-103003281-A | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors | HOFFMANN LA ROCHE | 2013-03-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | JAK3 7/4885JAK2 3/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.